注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Mesoblast Ltd是一家从事危重炎症同种异体细胞药物研发的公司。该公司利用其间充质谱系细胞技术平台开发同种异体细胞药物,并将其商业化,用以治疗复杂的炎症疾病。其候选药品包括Remestemcel-L(RYONCIL)用于治疗类固醇难治性急性移植物抗宿主病(SR-aGVHD)、Rexlemestrocel-L(REVASCOR)用于治疗晚期慢性心力衰竭(CHF),MPC-06-ID用于治疗腰椎椎间盘退化(CLBP)引起的慢性腰痛,其候选药品MPC-150-IM用于治疗或预防慢性心力衰竭,MPC-25-IC用于治疗或预防急性心肌梗塞。该公司候选药品还包括MPC-300-IV,用于治疗生物难治性类风湿性关节炎和糖尿病肾病。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
William A. M. Burns | 72 | 2014 | Independent Non-Executive Vice Chairman |
Silviu Itescu | 64 | 2004 | Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director |
Eric A. Rose | 71 | 2013 | Chief Medical Officer & Executive Director |
Henry Krum | - | - | Member of Scientific Advisory Board |
Robert M. Graham | - | - | Member of Scientific Advisory Board |
Stephen Graves | - | - | Member of Scientific Advisory Board |
Joseph M. Lane | - | - | Member of Scientific Advisory Board |
Richard E. Gilbert | - | - | Member of Scientific Advisory Board |
Philip R. Krause | - | 2022 | Non Executive Director |
Joseph Robert Swedish | 72 | 2018 | Independent Non-Executive Director |
Philip James Facchina | 62 | 2021 | Independent Non-Executive Director |
Jane Catherine Bell | - | 2022 | Independent Non-Executive Chairman |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核